Here are three things to know.
- The drug is approved to treat adults with complicated urinary tract infections, including a type of kidney infection called pyelonephritis.
- Vabomere is an intravenous combination drug made up of meropenem — an antibiotic — and vaborbactam, which inhibits certain resistance mechanisms used by bacteria.
- Rempex Pharmaceuticals’ expects Vabomere to hit the market in the fourth quarter of this year.
More articles on supply chain:
US Bioservices to pay $13.4M to resolve kickback suit
Samsung widens stake in prescription drug market through partnership with Japanese pharmaceutical company
Patients brace for price of ‘breakthrough’ leukemia drug CTL019
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
